Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum,Cell

当前位置： X-MOL 学术 › Cell › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Cell ( IF 45.5 ) Pub Date : 2021-06-17 , DOI: 10.1016/j.cell.2021.06.020
Chang Liu ₁ , Helen M Ginn ₂ , Wanwisa Dejnirattisai ₃ , Piyada Supasa ₃ , Beibei Wang ₃ , Aekkachai Tuekprakhon ₃ , Rungtiwa Nutalai ₃ , Daming Zhou ₄ , Alexander J Mentzer ₅ , Yuguang Zhao ₄ , Helen M E Duyvesteyn ₄ , César López-Camacho ₃ , Jose Slon-Campos ₃ , Thomas S Walter ₄ , Donal Skelly ₆ , Sile Ann Johnson ₇ , Thomas G Ritter ₈ , Chris Mason ₈ , Sue Ann Costa Clemens ₉ , Felipe Gomes Naveca ₁₀ , Valdinete Nascimento ₁₀ , Fernanda Nascimento ₁₀ , Cristiano Fernandes da Costa ₁₁ , Paola Cristina Resende ₁₂ , Alex Pauvolid-Correa ₁₃ , Marilda M Siqueira ₁₂ , Christina Dold ₁₄ , Nigel Temperton ₁₅ , Tao Dong ₁₆ , Andrew J Pollard ₁₄ , Julian C Knight ₁₇ , Derrick Crook ₁₈ , Teresa Lambe ₁₉ , Elizabeth Clutterbuck ₁₄ , Sagida Bibi ₁₄ , Amy Flaxman ₁₉ , Mustapha Bittaye ₁₉ , Sandra Belij-Rammerstorfer ₁₉ , Sarah C Gilbert ₁₉ , Tariq Malik ₂₀ , Miles W Carroll ₂₁ , Paul Klenerman ₂₂ , Eleanor Barnes ₂₂ , Susanna J Dunachie ₂₃ , Vicky Baillie ₂₄ , Natali Serafin ₂₄ , Zanele Ditse ₂₄ , Kelly Da Silva ₂₄ , Neil G Paterson ₂ , Mark A Williams ₂ , David R Hall ₂ , Shabir Madhi ₂₄ , Marta C Nunes ₂₄ , Philip Goulder ₂₅ , Elizabeth E Fry ₄ , Juthathip Mongkolsapaya ₂₆ , Jingshan Ren ₄ , David I Stuart ₂₇ , Gavin R Screaton ₁

Affiliation

Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Peter Medawar Building for Pathogen Research, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.
Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
Fundação de Vigilância em Saúde do Amazonas, Manaus, Amazonas, Brazil.
Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.
Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham Maritime, Kent ME4 4TB, UK.
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand; Department of Medicine, University of Oxford, Oxford, UK.
South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Peter Medawar Building for Pathogen Research, Oxford, UK; Department of Paediatrics, University of Oxford, Oxford, UK.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Diamond Light Source Ltd., Harwell Science & Innovation Campus, Didcot, UK; Division of Structural Biology, The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

中文翻译：

疫苗和恢复期血清对 SARS-CoV-2 B.1.617 的中和作用减少

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 已经发生了渐进性变化，具有优势的变体迅速成为优势谱系，例如 B.1.617。由于传播性明显增强，B.1.617.2 变种导致了当前肆虐印度次大陆的感染浪潮，并已被指定为英国关注的变种。在这里，我们研究单克隆抗体以及恢复期和疫苗血清中和 B.1.617.1 和 B.1.617.2 的能力，通过 Fab/受体结合域 (RBD) 复合物的结构分析对其进行补充，并绘制当前的抗原空间图变体。与祖先的武汉相关毒株相比，这两种病毒的中和作用均有所减少，但没有证据表明 B.1.351 中存在广泛的抗体逃逸。然而，B.1.351 和 P.1 血清显示 B.1.617.2 的中和作用显着减少，表明先前被这些变体感染的个体可能更容易被 B.1.617.2 再次感染。这一观察结果为非免疫人群未来变异疫苗的免疫政策提供了重要的新见解。

更新日期：2021-08-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11